Survival analysis of MPN-AP/BP patients treated with combination decitabine and ruxolitinib. (A) OS from the time of study enrollment. The median OS for all patients on study was 9.5 (95% CI, 4.3-12.0) months. (B) OS by TP53 status. Median OS for TP53 mutated patients was 7.6 (95% CI, 4.3-NE) and 9.6 (95% CI, 3.6-NE) months in TP53 nonmutated patients (P = .78).